The company’s revolutionary platform focuses on both regenerative and reprogramming medicine.  Fate's regenerative medicine platform involves developing drugs that awaken adult stem cells in the body to repair damaged cells and tissues.  Fate's reprogramming medicine platform involves developing drugs to reprogram mature adult cells into stem cells which when differentiated can become healthy heart, bone, brain or other tissues. 

Applications of these two approaches include treating the effects of neurological diseases such as Down syndrome, Alzheimer’s and Parkinson’s; healing damaged heart tissue after heart attacks; increasing bone and muscle strength in the severely frail; and protecting organs after infection or transplantation.  Fate will also tackle devastating cancers, such as pancreatic and colorectal cancer, by developing drugs to prevent the expansion and maturation of cancer stem cells.  

The company is led by a collaborative team from the most respected research institutions in the United States – Harvard, Stanford, the University of Washington, the Scripps Research Institute and Massachusetts General Hospital – along with world-class investors and management leadership with exceptional backgrounds in pharmaceuticals and medical technology.